<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01872260</url>
  </required_header>
  <id_info>
    <org_study_id>CLEE011X2107</org_study_id>
    <secondary_id>2013-001219-57</secondary_id>
    <nct_id>NCT01872260</nct_id>
  </id_info>
  <brief_title>Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer</brief_title>
  <official_title>A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to inform the future clinical development of the two
      investigational agents in ER+ breast cancer, LEE011 (CDK4/6 inhibitor) and BYL719 (PI3K-alpha
      inhibitor).

      This is a multi-center, open-label Phase Ib study. The Phase Ib dose escalation will estimate
      the MTD and/or RP2D for three regimens: two double combinations, LEE011 with letrozole and
      BYL719 with letrozole, followed by triple combinations of LEE011 + BYL719 with letrozole
      (Arms 3 and 4).

      The Phase Ib dose escalation part will be followed by Phase Ib dose expansions to further
      characterize the safety, tolerability, PK and preliminary clinical anti-tumor activity of the
      combinations. Optional crossover for patients who have progressed while on dose escalation or
      dose expansion with doublet treatment on Arms 1 or 2 to be treated with the triplet
      combination (Arm 3) after the determination of the RP2D for Arm 3; is no longer permitted
      after protocol amendment 6.

      Approximately 250 adult women with ER+/HER2- locally advanced or metastatic breast cancer
      will be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2013</start_date>
  <completion_date type="Anticipated">May 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose limiting toxicities (DLTs) - Phase lb only</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Average 18 months</time_frame>
    <description>Adverse Events (AEs), serious AEs (SAEs), changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, reductions and dose intensity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK profiles of LEE011 and letrozole</measure>
    <time_frame>18 months</time_frame>
    <description>To characterize PK profiles of LEE011 and Letrozole.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of LEE011 in combination with letrozole, BYL719 in combination with letrozole, and the triple combination of LEE011 +BYL719 with letrozole</measure>
    <time_frame>Average 24 months</time_frame>
    <description>Safety and tolerability will be determined by type, frequency and severity of adverse events and laboratory abnormalities per Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration-time profiles of LEE011, BYL719 and letrozole</measure>
    <time_frame>Average 24 months</time_frame>
    <description>To characterize the PK profiles of LEE011, BYL719, and letrozole when used in combination as well as to evaluate any other clinically significant metabolites that may be identified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Average 24 months</time_frame>
    <description>ORR is defined as the proportion of patients with a best overall response of complete response or partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Average 24 months</time_frame>
    <description>DOR is calculated as the time from the date of first documented response (complete response (CR) or partial response (PR)) to the first documented date of progression or death due to underlying cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Average 24 months</time_frame>
    <description>PFS is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters, including but not limited to AUCtau, Cmin, Cmax, Tmax, accumulation ratio (Racc)</measure>
    <time_frame>Average 24 months</time_frame>
    <description>To characterize the PK profiles of LEE011, BYL719, and letrozole when used in combination as well as to evaluate any other clinically significant metabolites that may be identified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the triple combination of LEE011 +BYL719 with letrozole in patients previously treated with either doublet</measure>
    <time_frame>Average 24 months</time_frame>
    <description>Safety and tolerability will be determined by type, frequency and severity of adverse events and laboratory abnormalities per Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">253</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>LEE011 + letrozole Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating), letrozole - 2.5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BYL719 + letrozole Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BYL719 - daily (dose escalating) letrozole - 2.5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEE011 + BYL719 + letrozole Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEE011 - 28 day cycles (21 days followed by a 7 day break -dose escalating), BYL719 - daily (dose escalating), letrozole 2.5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEE011+ BYL719+letrozole Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEE011-daily (dose escalating), BYL719 -daily (dose escalating), letrozole 2.5 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <description>LEE011 - 28 day cycles (21 days followed by a 7 day break) for Arms 1, 3. LEE011 28 days cycles (continuous) Arm 4.</description>
    <arm_group_label>LEE011 + letrozole Arm 1</arm_group_label>
    <arm_group_label>LEE011 + BYL719 + letrozole Arm 3</arm_group_label>
    <arm_group_label>LEE011+ BYL719+letrozole Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole 2.5 mg/day</description>
    <arm_group_label>LEE011 + letrozole Arm 1</arm_group_label>
    <arm_group_label>BYL719 + letrozole Arm 2</arm_group_label>
    <arm_group_label>LEE011 + BYL719 + letrozole Arm 3</arm_group_label>
    <arm_group_label>LEE011+ BYL719+letrozole Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BYL719</intervention_name>
    <description>BYL719 - 28 days cycle (continuous) for Arm 1; 3 and 4</description>
    <arm_group_label>BYL719 + letrozole Arm 2</arm_group_label>
    <arm_group_label>LEE011 + BYL719 + letrozole Arm 3</arm_group_label>
    <arm_group_label>LEE011+ BYL719+letrozole Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal, Estrogen-receptor positive and/or Progesterone-receptor positive
             breast cancer

          -  Phase Ib dose escalation only: Any number of prior lines of endocrine therapy is
             allowed with the exception of cytotoxic therapy which is limited to one prior line
             administered in the advanced (metastatic or locally advanced) setting.

          -  Phase Ib dose expansions Arms 1, 2 and 3

          -  No prior systemic treatment in the advanced (metastatic or locally advanced) setting
             with the exception of treatment with letrozole for a maximum of one month prior to
             starting study treatment.

          -  Patients who received (neo)adjuvant therapy for breast cancer are eligible. Prior
             therapy with letrozole or anastrozole in the (neo)adjuvant setting is permitted if the
             disease-free interval is greater than 12 months from the completion of treatment.

        Exclusion Criteria:

          -  HER2-overexpression in the patient's tumor tissue

          -  Patients with active CNS or other brain metastases

          -  Major surgery within 2 weeks

          -  Acute or chronic pancreatitis

          -  Bilateral diffuse lymphangitic carcinomatosis

          -  Another malignancy within 3 years

          -  Receiving hormone replacement therapy that cannot be discontinued

          -  Impaired cardiac function

          -  Patients with clinically manifest diabetes mellitus (treated and/or clinical signs or
             with fasting glucose ≥ 126 mg/dL / 7.0 mmol/L or hemoglobin A1c &gt;6.5%), history of
             gestational diabetes mellitus or documented steroid-induced diabetes mellitus.

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California at San Diego, Moores Cancer Ctr Dept. of Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela F. Doering</last_name>
      <phone>858-822-5352</phone>
      <email>mdoering@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Teresa Helsten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Onc Dept</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyson Cockerill</last_name>
      <phone>415-514-6245</phone>
      <email>CockerillA@cc.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela Munster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Dunning</last_name>
      <phone>813-745-1807</phone>
      <email>Beverly.Dunning@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Hyo Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital SC-5</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dejan Juric, MD</last_name>
      <phone>617-726-6500</phone>
      <email>Juric.Dejan@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Dejan Juric</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center SC</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Perry</last_name>
      <phone>603-650-6425</phone>
      <email>Tanya.m.perry@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Peter Kaufman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI SC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda T Mundy</last_name>
      <phone>+1 615 329 7432</phone>
      <email>amanda.mundy@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Erika Paige Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center Vanderbilt - Thompson Ln</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula K. Halmon</last_name>
      <phone>615-936-1164</phone>
      <email>ursula.a.halmon@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Ingrid A. Mayer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Texas Oncology - Sammons</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K Cassinda Zaehringer</last_name>
      <phone>+1 214 370 1916</phone>
      <email>cassinda.zaehringer@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carlos Roberto Becerra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital / Methodist Cancer Center Dept of Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Williams</last_name>
      <phone>+1 713 441 6011</phone>
      <email>cjwilliams2@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Tejal Augusto Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research Center / UT Health Science Center Dept of Onc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Jones</last_name>
      <phone>210-450-5715</phone>
      <email>Jonese5@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Kate B. Lathrop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Byers</last_name>
      <phone>206-448-4082</phone>
      <email>abyers@nwmsonline.com</email>
    </contact>
    <investigator>
      <last_name>Sibel Blau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Herblain cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 9BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Hong Kong</country>
    <country>Israel</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hormone-receptor positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

